Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

[1]  E. Vasile,et al.  Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. , 2016, Future oncology.

[2]  Yan-Shen Shan,et al.  Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.

[3]  E. Vasile,et al.  P-180Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients: a single institution retrospective cohort study , 2015 .

[4]  J. Taïeb,et al.  Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM). , 2014, European journal of cancer.

[5]  Karin Haustermans,et al.  Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). , 2014, European journal of cancer.

[6]  B. Dörken,et al.  Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Taieb,et al.  FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study , 2014, BMC Cancer.

[8]  David Cunningham,et al.  O-0003NAPOLI-1: RANDOMIZED PHASE 3 STUDY OF MM-398 (NAL-IRI), WITH OR WITHOUT 5-FLUOROURACIL AND LEUCOVORIN, VERSUS 5-FLUOROURACIL AND LEUCOVORIN, IN METASTATIC PANCREATIC CANCER PROGRESSED ON OR FOLLOWING GEMCITABINE-BASED THERAPY , 2014 .

[9]  M. Moore,et al.  PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT). , 2014 .

[10]  K. Perez,et al.  Nab-paclitaxel (nab-P) combined with FOLFOX for advanced pancreatic cancer: A phase I study. , 2014 .

[11]  N. Siauve,et al.  Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy. , 2014, Clinics and research in hepatology and gastroenterology.

[12]  H. Soares,et al.  A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere , 2014, Cancer Chemotherapy and Pharmacology.

[13]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[14]  S. Steinberg,et al.  Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Seung June Lee,et al.  5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy , 2013, Chemotherapy.

[16]  I. Reis,et al.  A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer , 2013, American journal of clinical oncology.

[17]  Isabelle Salmon,et al.  Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. , 2012, Gastroenterology.

[18]  I. Sobhani,et al.  5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma , 2011, Oncology.

[19]  B. Dörken,et al.  Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. , 2011, European journal of cancer.

[20]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[21]  B. Chauffert,et al.  Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301) , 2010, Gut.

[22]  D. Park,et al.  A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer , 2009, British Journal of Cancer.

[23]  A. Lièvre,et al.  Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: feasibility and potential benefits in a retrospective series of 117 patients. , 2009, Gastroenterologie clinique et biologique.

[24]  Arnold Knijn,et al.  EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. , 2009, European journal of cancer.

[25]  A. Sparreboom,et al.  Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. , 2006, Current neuropharmacology.

[26]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[27]  Daniel,et al.  There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. , 1998 .

[28]  E. Giovannetti,et al.  Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer. , 2014, Anticancer research.

[29]  E. Diamandis,et al.  Pancreatic cancer. , 2013, Clinical chemistry.

[30]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[31]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[32]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.